Prediction models for colorectal cancer (CRC) detection in symptomatic patients, based on easily obtainable variables such as fecal haemoglobin concentration (f-Hb), age and sex, may simplify CRC diagnosis. We developed, and then externally validated, a multivariable prediction model, the FAST Score, with data from five diagnostic test accuracy studies that evaluated quantitative fecal immunochemical tests in symptomatic patients referred for colonoscopy. The diagnostic accuracy of the Score in derivation and validation cohorts was compared statistically with the area under the curve (AUC) and the Chi-square test. 1,572 and 3,976 patients were examined in these cohorts, respectively. For CRC, the odds ratio (OR) of the variables included in the Score were: age (years): 1.03 (95% confidence intervals (CI): 1.02-1.05), male sex: 1.6 (95% CI: 1.1-2.3) and f-Hb (0-<20 mg Hb/g feces): 2.0 (95% CI: 0.7-5.5), (20-<200 mg Hb/g): 16 .8 (95% CI: 6.6-42.0), 200 mg Hb/g: 65.7 (95% CI: 26.3-164.1). The AUC for CRC detection was 0.88 (95% CI: 0.85-0.90) in the derivation and 0.91 (95% CI: 0.90-093; p 5 0.005) in the validation cohort. At the two Score thresholds with 90% (4.50) and 99% (2.12) sensitivity for CRC, the Score had equivalent sensitivity, although the specificity was higher in the validation cohort (p < 0.001). Accordingly, the validation cohort was divided into three groups: high (21.4% of the cohort, positive predictive value-PPV: 21.7%), intermediate (59.8%, PPV: 0.9%) and low (18.8%, PPV: 0.0%) risk for CRC. The FAST Score is an easy to calculate prediction tool, highly accurate for CRC detection in symptomatic patients.
Colorectal cancer (CRC) remains an important health problem in Western Europe. It is the seventh cause of death and the fourth cause of years of life lost. 1 Health authorities have developed two main strategies to reduce the impact of CRC: screening in average and, on occasion, high-risk (personal or family history of CRC or adenomas) populations, and prompt detection in symptomatic patients. [2] [3] [4] [5] [6] Although screening programmes are being progressively implemented, most CRC are detected when symptoms become apparent. 7 In addition, although gastrointestinal symptoms are extremely common in the population, the probability of CRC detection associated with any one symptom is low. [8] [9] [10] Which symptomatic patients should be evaluated promptly, mainly with colonoscopy, is the dilemma in any diagnostic strategy. Over-investigation generates financial costs and patients are subjected to psychological impact and unnecessary endoscopyrelated risk and discomfort. On the other hand, lack of investigation risks a delay in diagnosis with clinical and possibly medicolegal impact. In order to reach a balance, several approaches that use criteria for referral for colonoscopy that are associated with a high risk for CRC have been established. In this regard, the best known guidelines are the very detailed and extremely prescriptive National Institute for Health and Care Excellence (NICE) criteria for suspected cancer. 3, 11 Additionally, a number of CRC prediction models have been designed and validated in different settings. These prediction models, systematically reviewed in detail recently, are calculated from mathematical equations based mainly on symptoms, although information regarding demographics, other variables and results of investigations are
What's new? Lower gastrointestinal symptoms potentially indicative of colorectal cancer (CRC) are a common reason for physician visits. While the probability that any one of those symptoms is associated with CRC is low, identifying patients for further screening remains a challenge. Here, the possibility of improving CRC diagnostic accuracy and risk stratification was explored using a three-variable FAST Score based on fecal hemoglobin concentration, age, and sex. Among symptomatic patients referred to colonoscopy, the FAST Score prediction model identified three risk groups, the lowest of which ruled out CRC. Threshold scores were sensitive across variables, including country, age, and sex.
sometimes also included. 12 Although their diagnostic accuracy is generally deemed to be satisfactory and better than the existing referral criteria, these prediction models have not been widely implemented, in part due to their complexity and the difficulty of collection of all of the spectrum of variables required. [13] [14] [15] Fecal immunochemical tests for haemoglobin (FIT) have proven to be the best currently available non-invasive test for CRC screening in asymptomatic individuals and an excellent test for rule-in of CRC and rule-out of significant colonic lesions (SCL) in patients presenting with lower gastrointestinal symptoms. [16] [17] [18] [19] [20] [21] Quantitative FIT allow for assessment of fecal hemoglobin concentration (f-Hb). There are several prediction models in asymptomatic individuals for CRC screening based on f-Hb, 22 and a CRC prediction model in symptomatic patients including f-Hb has been recently developed and externally validated. 23 This prediction model was shown to have high diagnostic accuracy and discriminated between three risk groups, one of them with a negligible risk for CRC. However, its applicability may be limited due to its complexity, since the model includes eleven variables.
In consequence, we carried out a derivation and external validation multivariable prediction model study, based on the hypothesis that a simple to calculate risk score, based on only three readily available variables-f-Hb, age and sex-could simplify the evaluation of symptomatic patients and provide a easy to use tool for the risk stratification of these to facilitate prioritisation of referrals for endoscopy. 20 In order to perform this study on the FAST Score, detailed data obtained in five previously peer-reviewed and published studies evaluating the diagnostic accuracy of FIT in 5,548 symptomatic patients referred for colonoscopy were used. [16] [17] [18] [19] [20] [21] 23 Patients and Methods
Design
The development and external validation of the multivariable prediction model was designed according to the TRIPOD guidelines. 24 All diagnostic accuracy studies from which data were derived for this work were performed according to the STARD guidelines, 25 as documented in the relevant publications. [16] [17] [18] [19] [20] [21] 23 
Derivation cohort
The derivation cohort consisted of 1,572 consecutive symptomatic patients referred to colonoscopy in Ourense, Spain, between March 2012 and September 2013, who were included in the derivation cohort of the COLONPREDICT study. 23 The exclusion criteria have been detailed elsewhere. 23 All patients collected one fecal sample from a single bowel movement during the week before the colonoscopy. They were specifically instructed to sample the passed feces where no blood was visible. f-Hb was determined using the automated OC-SENSOR MICRO analyzer (Eiken Chemical, Tokyo, Japan). Colonoscopy was performed blind to the analytical results. The characteristics of this derivation cohort and the main endoscopic findings are shown in Table 1 .
Validation cohort
The validation cohort included 3,976 symptomatic patients recruited in five studies evaluating the diagnostic accuracy of different FIT analytical systems for CRC, advanced neoplasia (AN), and significant colonic lesion (SCL) detection or exclusion in symptomatic patients. 17, [19] [20] [21] 23 The characteristics of the different cohorts with respect to age, sex, colonoscopy findings, reasons for primary care referral and FIT system used are shown in Table 1 . The particulars of these five studies are documented in detail in the relevant publications. [17] [18] [19] [20] [21] All studies were approved by the local Clinical Research Ethics Committees and patients provided written informed consent in the Spanish studies. In the three Scottish studies, Research Ethics Committees stated that, if the patient returned a sample for f-Hb measurement, consent was implied. Estimates of f-Hb were quantitated as mg Hb/g feces so that results could be compared across analytical systems. 26 
Main outcome
The main outcome of this study was CRC detection. The secondary outcomes were advanced neoplasia (AN) and significant colonic lesions (SCL) diagnosis. AN was defined in the Spanish studies as advanced adenomas (10 mm, villous histology, high-grade dysplasia) or CRC and, in the studies done in Scotland, more simply as higher-risk adenoma (>10 mm, or more than three) or CRC. SCL was defined in Spain as any of the following: CRC, AN, polyposis (>10 polyps of any histology, including serrated lesions), colitis (any aetiology), polyps 10 mm (including serrated lesions), complicated diverticular disease (diverticulitis, bleeding), colonic ulcer or bleeding angiodysplasia, In Scotland, again more simply, SCL was defined as any of CRC, AN or inflammatory bowel disease (IBD-Crohn's or ulcerative colitis); other lesions (non-advanced adenomas, non-complicated diverticular disease, polyps <10 mm, non-bleeding angiodysplasia, haemorrhoids) were considered non-significant colonic lesions.
Development of the prediction tool
Three variables were included in the FAST Score prediction tool: the acronym is based on the Fecal haemoglobin concentration, Age and Sex Test Score. Before logistic regression, we performed a univariate analysis using Generalized Additive Model models with smoothing splines for continuous variables. The objective of this analysis was to determine, in those nonlinear variables, the different strata or classes. Age was introduced as a continuous variable. In contrast, f-Hb had to be introduced as a categorical variable since it is not appropriate for introduction as a continuous variable in a logistic regression model. This is because f-Hb did not have a normal distribution, even after logarithmic transformation; in addition, the risk of CRC did not have a linear relationship to f-Hb in spite of f-Hb being related to colonic disease severity. On account of previous findings, [16] [17] [18] [19] [20] [21] we decided to use three
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Cubiella et al. thresholds in f-Hb concentration: 0 mg Hb/g feces (with the theoretical potential to rule out CRC and SCL), 19, 21 20 mg Hb/g feces (the threshold used in many CRC screening programmes) and, finally, 200 mg Hb/g feces, the upper limit of the analytical working range of the most commonly used FIT analytical system, the OC-Sensor. (Eiken) In consequence four categories were defined: (i) 0 mg Hb/g feces, (ii) between 0 and below 20 mg Hb/g feces, (iii) between 20 and below 200 mg Hb/g feces and (iv) >200 mg Hb/g feces. The regression coefficients were used to construct a CRC prediction Score, where the dependent variable was the presence or absence of CRC. We calculated the area under the curve (AUC) from the receiver operating characteristic (ROC) curve analyses. The calibration of the model in the derivation cohort was evaluated with the Hosmer-Lemeshow test
In order to evaluate the diagnostic yield of the final prediction tool, two threshold Scores were established with 90 and 99% sensitivity for CRC detection, and the diagnostic accuracy for CRC, AN and SCL were determined at each of these thresholds. Using these threshold Scores, the cohorts were dissected into three groups: high, intermediate and low risk for CRC detection. The number of patients, the positive predictive value (PPV) and the number needed to scope (NNS) to detect one CRC, AN or SCL were calculated for each group. Finally, we expressed the differences in risk as Odds Ratios (OR) with 95% confidence intervals (CI).
External validation
We used the coefficients to calculate the FAST score for each patient in the validation dataset. Those patients that met the criteria for 90 and 99% sensitivity were determined. The diagnostic accuracy of the model in the derivation and the validation cohorts were compared with, first, with the AUC derived from ROC curves and, second, with the v 2 test to determine differences in sensitivity and specificity at the two threshold Scores between the cohorts for CRC, AN and SCL detection. The calibration of the model in the validation cohort was evaluated with the Hosmer-Lemeshow test.
Diagnostic accuracy according to additional variables
Finally, a post-hoc analysis of the model was performed in the validation cohort to determine if its diagnostic accuracy for CRC detection was altered on the basis of the level of healthcare at which the patient was referred for colonoscopy (primary or secondary), the country in which the study was performed (Spain or Scotland), the CRC prevalence (<5% or >5%) in the study group, sex (male or female), age (<50 or 50 years), the individual study and, finally, the particular FIT analytical system used to estimate f-Hb. In order to perform this analysis, diagnostic accuracy was compared with AUC derived from ROC curves and sensitivity and specificity with the v 2 test. Data are reported with 95% CI. A p values <0.05 was considered to be statistically significant. Analysis was carried out using SPSS statistical software, version 15.0 (SPSS, Chicago, IL) and EPIDAT 3.1 (Direcci on Xeral de Sa ude P ublica, Santiago de Compostela, Spain).
Results

Development of the score prediction model
The odds ratio (OR) of the variables included in the model were: age (years): 1.03, 95% (CI 1.02-1.05), male sex: 1.6 (95% CI: 1.1-2.3) and f-Hb (0-<20 mg Hb/g feces): 2.0 (95% CI: 0.7-5.5), (20- 
Diagnostic accuracy of the score in the derivation cohort
The thresholds for the b-coefficient of the FAST Score with 90 and 99% sensitivity were 4.50 and 2.12, respectively. The b-coefficient was at least 4.50 in 37.1% and 2.12 in 88.0% of the patients included in the derivation cohort. Data on the diagnostic accuracy of the Score for CRC detection using these two threshold Scores are shown in Table 2 . The overall AUC for AN detection was 0.82 (95% CI: 0.80-0.84) and for SCL was 0.82 (0.79-0.84). At the threshold Score of 4.50, the tool had a sensitivity for AN and SCL detection of 75.4% (95% CI: 70.9-79.4) and 72.7% (95% CI: 68.4-76.7), respectively. Moreover, at the threshold Score of 2.12, the sensitivity rose to 98.8% (95% CI: 97.1-99.6) and 97.8% (95% CI 95.9-98.9) for AN and SCL, respectively.
According to these two threshold Scores, the derivation cohort was dissected into three risk groups: high (Score 4.50), intermediate (Score <4.50 and 2.12) and low (Score <2.12). The diagnostic yields of this classification for CRC, AN and SCL detection are shown in Table 3 . In summary, while the NNS to detect a CRC, or an AN, or a SCL were 35.7, 8.1, and 6.9 in the intermediate-risk group, the NNS in the high-risk group were 3.0, 1.8 and 1.7, respectively. No CRC was detected in the low-risk group and the NNS to detect an AN, or a SCL in this group rose to 37.0 and 18.9. The OR in the high-risk group for CRC detection was 17.5 (95% CI: 11.1-27.8) when compared with the intermediate-risk group.
Validation of the score in the validation cohort
In the ROC analysis, the FAST Score was more accurate for CRC detection in the validation cohort (AUC: 0.91, 95% CI: 0.90-0.93; p 5 0.005) as shown in Figure 1 . This difference in the diagnostic accuracy was related to a statistically significant increase in specificity in the validation cohort as shown in Table 4 . In contrast, there were no differences in sensitivity for CRC detection between the two cohorts. With respect to the calibration in the validation cohort, the HosmerLemeshow test significance was p 5 0.01. In addition, the
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Cubiella et al. Although the specificity for these two groups of colonic disease was also significantly increased in the validation cohort, the sensitivity was also reduced. These differences in sensitivity and specificity also occurred when comparing the data from the Scottish and Spanish studies (Supporting Information Table 1 ).
The FAST Score also discriminates the risk of CRC, AN and SCL detection in the validation cohort as shown in Table  3 . In this regard, 851 patients (21.4%) met high-risk group criteria with a 21.7% PPV for CRC detection; 2,378 (59.8%) met intermediate-risk group criteria with a 0.9% PPV and, finally, 747 (18.8%) patients met low-risk group criteria with a 0.0% PPV for CRC detection in the validation cohort.
Diagnostic accuracy in the validation cohort according to the characteristics of the groups
In the post-hoc analysis, possible differences in the diagnostic accuracy of the FAST Score for CRC detection were assessed in the validation cohort according to several variables, as shown in Table 5 . No significant differences in sensitivity for CRC detection were detected in any of the groups assessed. In addition, no differences were found in the diagnostic accuracy when comparing the patients referred for colonoscopy from primary care with those referred from secondary care. In contrast, the diagnostic accuracy, either overall or as specificity, was increased in the groups with a lower CRC prevalence. In this respect, differences were found in the CRC prevalence according to sex (male: 7.1%, female: 3.6%, p < 0.001), age (<50 years: 1.3%, 50 years: 6.1%; p < 0.001) and country (Spain: 6.5%, Scotland: 3.0%, p < 0.001). In contrast, the CRC prevalence was similar in both healthcare levels referring patients (primary: 5.6%, secondary: 4.9%, p 5 0.4). Finally, the diagnostic accuracy was compared between the most commonly used analytical system (OCSensor) and the other analytical methods used, including the widely used HM-JACKarc, and between the validation cohort of the COLONPREDICT study and the rest of the study groups. As shown in Table 5 , diagnostic accuracy was equal or higher with respect to the validation cohort, both for the analytical system and the study groups.
Discussion
Statement of principal findings
Because f-Hb is dependent on age and sex, 27 we developed and assessed the diagnostic accuracy of an easy to calculate prediction tool based not only on f-Hb, as originally Values are expressed as percentages with 95% confidence intervals in parentheses. 4 Values are expressed as absolute numbers and 95% confidence intervals in parentheses.
NE: not evaluable.
suggested by Chen et al, 28 but also age and sex. 20 This prediction tool, termed the FAST Score, is highly accurate for CRC detection in symptomatic patients and allows establishment of three risk groups: CRC can be ruled out in those in the lowest risk group. In addition, we have confirmed that the threshold Scores we have examined are equally sensitive for CRC irrespective of, country, CRC prevalence, age, sex, healthcare level and analytical system used to estimate f-Hb. In contrast, this prediction tool was less accurate for AN and SCL detection in the validation cohort.
Strengths and weaknesses of the study
We had the opportunity to access the individual data of the patients included in five of the six studies that have evaluated different analytical systems for the measurement of f-Hb in symptomatic patients referred for colonoscopy. [16] [17] [18] [19] [20] [21] These studies have evaluated the application of FIT in a wide variety of clinical settings with differences in the strategy for invitation to the study, the analytical systems, the referral criteria to colonoscopy and the epidemiological characteristics of the cohorts included (age, sex and CRC, AN and SCL prevalence). On the basis of these data, we have developed and externally validated a multivariable prediction tool according to the TRIPOD guidelines 24 A CRC prediction model, COLONPREDICT, had been previously developed and validated. 23 This prediction model was compared with the NICE referral guidelines used at that time 3 demonstrating that a prediction model using f-Hb and other variables was more accurate than symptom-based referral criteria. 23 In the case of the FAST Score, its greatest advantage is simplicity and it 
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could be calculated automatically by laboratory information management systems (LIMS) widely used to report results in laboratory medicine, with or without appropriate interpretative comments added by the LIMS, or through simple calculators developed for the Internet or as easy to download apps, since age and sex are generally available in health care systems and, if not, are easily collected from patients with symptoms prior to referral for colonoscopy along with the fHb. We think the simplicity of this prediction model may encourage the implementation of the FAST Score in comparison with previous developed prediction models for CRC detection that are based on several clinical and analytical variables which must be collected from disparate sources before the model is applied, [12] [13] [14] [15] The FAST Score allows the rapid allocation of a patient to one of three risk groups: a high risk group where 90% of CRC are detected and these might be referred on an urgent basis, an intermediate risk group where 9% additional CRC are detected and such patients might be assessed further before referral, and a low risk group where, hypothetically, the remaining 1% would be found. This low risk group, with a negligible PPV accounts for nearly 19% of the validation cohort and these patients would probably not benefit from colonoscopy or possibly any further examination. In contrast, the NICE referral criteria for suspected CRC have a 68.2% sensitivity and a 50.2% specificity for CRC detection, and, in reality, these criteria cannot rule out CRC. 23 The main weakness of our study is that the patients included in these studies had been selected a priori by health care professionals for further endoscopic evaluation. In consequence, we believe that the diagnostic accuracy of the FAST Score that we have developed should be externally evaluated in a population with gastrointestinal symptoms attending primary care before its use is widely adopted. In fact, our findings strongly suggest that the FAST Score diagnostic accuracy will increase in populations in which CRC is at a low prevalence since this will result in an increase in specificity. We also propose that our fHb, age and sex based prediction tool should be compared within a randomized controlled trial with the currently available referral guidelines, such as the recent recommendations from NICE 11 in terms of sensitivity, efficiency (endoscopy referrals to detect a CRC, delays) and, finally, effect on CRC survival. 29 Additionally, we have found significant differences in the calibration of the model in the validation cohort, probably related to the differences in the CRC prevalence between the derivation (13.7%) and the validation cohort (5.2%). These differences do not reduce the value of our findings. The prediction model is not aimed at estimating the individual risk but, rather, to determine different diagnostic strategies in symptomatic patients. However, the FAST Score will require not only validation in primary healthcare but also recalibration in this setting before using it to provide risk-adjusted outcomes.
Another limitation is the reduced diagnostic accuracy for detection of additional SCL. In part, this might be related to the different definitions used in the studies for AN and SCL in Spain and in Scotland. On the other hand, although this reduced accuracy could be considered as a limitation, there are several arguments to support use of the FAST Score in this broader clinical perspective. First, there are very few data published on AN detection models and tools, 12, 20 but there is no model or tool published to date for SCL detection, apart from the more complex COLONPREDICT score. As is widely recognized, there are criteria for the appropriateness of colonoscopy referral. These criteria have been evaluated in a prospective fashion showing that their diagnostic accuracy for both CRC and SCL detection is limited. As one example, a meta-analysis has shown that the diagnostic OR of the American Society for Gastrointestinal Endoscopy and European Panel on the Appropriateness of Gastrointestinal Endoscopy (EPAGE) criteria for 1 Values are expressed as percentages with 95% confidence intervals in parentheses. 2 Significance of the sensitivity and specificity differences between both cohorts in the v 2 test. Differences with p < 0.05 are considered statistically significant. 3 Advanced neoplasia 5 colorectal cancer plus advanced adenoma (see text). 4 Significant colonic lesion 5 colorectal cancer plus advanced adenoma (see text) plus other significant pathology (see text). NE: non-evaluable.
relevant findings was 2.5 (95% CI: 1.2-5.6), 30 inferior to the OR of the FAST Score in both derivation and the validation cohorts. Further, although we cannot exclude relevant findings in the low risk group (PPV: 5.2-5.3%), the PPV in the inappropriate colonoscopy group according to the EPAGE II criteria ranges between 9.5 and 24.5%. 31, 32 Finally, it is quite clear that the main endpoint of endoscopic evaluation of symptomatic patients must be the detection, or perhaps more importantly, the exclusion of those clinical conditions that threaten or significantly affect the quality of life, especially on account of the limited endoscopic resources available in many countries.
Strengths and weaknesses in relation to other studies, discussing important differences in results
The FAST Score was derived from the data from the same cohort as the COLONPREDICT score but, as commented previously, we had the opportunity to validate it in a wider geographical cohort. Both scores are tools based mainly on fHb. In the case of the FAST score, we applied f-Hb in four categories, one of them 0 mg Hb/g feces. Previous studies have shown the probability of ruling out CRC in patients with low f-Hb (<10 mg Hb/g feces) 20, 25 or f-Hb of 0 mg Hb/g feces. 17 However, although this was not the case in our study, patients with this f-Hb had a 0.5, 0.06 and 0.015-fold risk when compared with those patients with 0-20, 20-200 and 200 mg Hb/g feces, respectively.
In comparison with the COLONPREDICT score, the FAST Score has lower diagnostic accuracy. The COLONPRE-DICT score detects 90 and 99% CRC in 30.9 and 60.5% of the derivation cohort, in contrast with the FAST Score, that requires 37.1 and 88.0% of the cohort to achieve these levels. However, these data should be further evaluated in real routine practice. Unlike the FAST score, COLONPREDICT requires an anorectal examination, tests done on venous 1 Significance of the area under the curve differences between cohorts with the v 2 homogeneity test. Differences with p < 0.05 are considered statistically significant. 2 Significance of the sensitivity and specificity differences between cohorts with the v 2 test. Differences with p < 0.05 are considered statistically significant. 3 The cohorts are compared with the OC-Sensor cohort. 4 The cohorts are compared with the Cubiella et al. study cohort. AUC: area under the curve; CI: confidence interval; FIT: fecal immunochemical test for haemoglobin.
blood and a detailed history to be performed before its calculation. So, the increased accuracy of the COLONPREDICT score in a controlled setting may be limited in daily practice because of its complexity compared to the simplicity of the FAST score that only requires f-Hb, age and sex. That is why we think both approaches should be compared in a primary care setting in a future study.
Meaning of the study: Possible explanations and implications for clinicians and policymakers
Even though we now need to evaluate the applicability of the FAST Score in a routine primary care setting, the implications for clinicians and policymakers are quite clear. Prediction tools based on f-Hb measured by high quality automated quantitative FIT should be the cornerstone of the evaluation of the symptomatic patient and used as the criterion to determine the appropriateness of the referrals for colonoscopy. We consider that the FAST Score does provide an objective tool to guide who requires further investigation in secondary care. In fact, recently published (2015) NICE referral guidelines for suspected cancer have included the use of tests for the presence of occult blood in feces in symptomatic patients with a PPV for CRC detection below 3%. 11 However, we think that f-Hb-based prediction tools could be a better basis for the evaluation of all symptomatic patients.
Furthermore, we believe strategies for prompt diagnosis of patients with suspected CRC should be designed based on sensitivity rather than on the PPV. As an example, if we use the 3% PPV threshold for CRC for further evaluation determined in the 2015 NICE guidelines, 11 we would miss one out of ten CRC, since the PPV in the FAST intermediate risk group in the derivation and validation cohorts is 2.8 and 0.9%, respectively. Thus, we consider that prompt diagnosis strategies should determine a 90% sensitivity threshold for urgent referral and a 99% sensitivity referral threshold for colonoscopy evaluation. The secondary endpoint should be specificity as long as low specificity is associated with unnecessary referrals to colonoscopy, with its corresponding risks. In fact, the specificity of the FAST Score at the 90% sensitivity threshold seems acceptable when compared with other available clinical criteria, for example, NICE referral criteria. 18 In contrast, the specificity at the 99% sensitivity threshold is extremely low. However, it must be emphasized that, at this threshold, to the Score rules out CRC.
Unanswered questions and future research
Two main issues need to be answered in the future. As stated previously, the diagnostic accuracy and applicability of the FAST Score tool in a primary care setting must be addressed in a prospective study and, ideally, compared with the COLONPREDICT score and current age and symptom-based referral guidelines. Second, further prediction tools based on laboratory findings other than f-Hb should be designed and evaluated in a primary care setting. In this respect, the evaluation of newer CRC biomarkers in risk scoring models would be a necessary prerequisite to their introduction as investigations to assist the CRC diagnosis process in symptomatic patients.
